Sobi's commitment to developing innovative treatments for people living with rare diseases is highlighted in studies spanning several rare disorders, including haemophilia, paroxysmal nocturnal haemoglobinuria (PNH), chronic immune thrombocytopenia (ITP), macrophage activation syndrome (MAS) and haemophagocytic lymphohistiocytosis (HLH).įor the first time, the PRINCE phase 3 data on pegcetacoplan in adults with PNH who are treatment naïve – meaning they had not received a complement inhibitor within three months before entering the study – will be presented. 4, 2021 /PRNewswire/ - Sobi™ will present new data at the 63rd Annual Meeting of the American Society of Hematology (ASH) taking place from 11-14 December 2021.
